“This year, Insmed is going further by advancing more therapies into and through clinical development across our three therapeutic areas. At the same time, we are looking to broaden the impact of our two commercialized products, ARIKAYCE and BRINSUPRI, through potential expansion in MAC lung disease and appropriate diagnosis of bronchiectasis, respectively.”